249420.KS KSC
Ildong Pharmaceutical Co., Ltd.
1W: +4.8%
1M: +0.1%
3M: -13.8%
YTD: -60.0%
1Y: -30.6%
3Y: -10.1%
5Y: -9.9%
₩14,510.00 ($10.80)
-60.00 (-0.41%)
Weekly Expected Move ±6.4%
₩12643
₩13577
₩14510
₩15443
₩16377
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$19.0B
-33.0% ▼
5Y CAGR: -0.4%
Capital Expenditures
$13.6B
+2.9% ▲
5Y CAGR: -6.6%
Free Cash Flow
$5.3B
-62.8% ▼
5Y CAGR: +101.4%
Dividends Paid
$0
+100.0% ▲
Buybacks
$866K
-400.6% ▼
Net Change in Cash
-$7.4B
-139.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$101.0B | -$142.2B | -$78.9B | -$12.4B | $27.7B |
| Depreciation & Amort. | $29.3B | $29.5B | $28.3B | $25.9B | $22.6B |
| Stock-Based Comp. | $17M | $18M | $0 | $130M | $0 |
| Change in Working Capital | -$1.5B | -$14.4B | -$11.5B | -$8.0B | -$27.5B |
| Other Non-Cash Items | $10.4B | $73.5B | $25.5B | $22.7B | -$3.8B |
| Operating Cash Flow | -$11.4B | -$53.5B | -$36.6B | $28.3B | $19.0B |
| — Investing Activities — | |||||
| Capital Expenditures | -$19.8B | -$19.6B | -$18.2B | -$10.7B | -$17.3B |
| Acquisitions (Net) | $1.1B | $368M | $0 | $80M | -$15.9B |
| Investment Purchases | -$28.2B | -$74.7B | -$46.0B | -$16.8B | -$4.5B |
| Investment Sales | $5.0B | $67.3B | $44.4B | $29.5B | $26.1B |
| Other Investing | -$1.5B | $204M | -$571M | $16.3B | $9.3B |
| Investing Cash Flow | -$43.4B | -$26.4B | -$20.4B | $18.5B | -$2.3B |
| — Financing Activities — | |||||
| Net Debt Issuance | $99.4B | -$6.1B | $64.0B | -$23.5B | -$21.1B |
| Stock Repurchased | $0 | $0 | -$1.9B | -$173K | -$866K |
| Dividends Paid | $0 | -$120M | -$160M | -$77M | $0 |
| Other Financing | -$2.7B | $3.0B | -$3.8B | -$4.2B | -$3.0B |
| Financing Cash Flow | $104.3B | -$3.3B | $58.2B | -$27.9B | -$24.1B |
| Net Change in Cash | $50.0B | -$83.4B | $1.1B | $19.0B | -$7.4B |
| Cash End of Period | $135.6B | $52.1B | $53.3B | $72.3B | $64.8B |
| Free Cash Flow | -$31.2B | -$73.1B | -$54.8B | $14.2B | $5.3B |